Try our beta test site

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Quebec Clinical Research Organization in Cancer
Novartis
Hoffmann-La Roche
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT01238692
First received: November 10, 2010
Last updated: December 2, 2016
Last verified: December 2016